Insys Therapeutics, Inc.

Track this case

Case Number:

1:19-bk-11292

Court:

Delaware

Nature of Suit:

Firms

Companies

Government Agencies

Sectors & Industries:

November 06, 2019
Insys Creditors Say Liquidation Would Spark Chaos

Opioid maker Insys Therapeutics' unsecured creditors fired back in Delaware bankruptcy court Tuesday at calls from government bodies involved in an opioid suit to liquidate the company, calling them an attempt to press an inflated claim that would plunge creditors into a yearslong free-for-all over the estate.
November 04, 2019
Insys Ch. 11 Disclosures Draw Fire From DOJ, US Trustee

The U.S. Department of Justice and the Office of the United States Trustee objected Monday to the proposed Chapter 11 plan disclosure statement of bankrupt opioid maker Insys Therapeutics, saying it doesn't include enough information and that the plan can't be confirmed.
November 01, 2019
Insys MDL Group Slams Del. Ch. 11 Doc As Fatally Flawed

Opioid multidistrict litigation claimholders branded Insys Therapeutics' Delaware Chapter 11 disclosure statement as "unapprovable" late Friday, in an objection that described the document as an unsupportable and "fatally misleading" effort to hide unfair treatment of different creditor groups.
October 08, 2019
Insys Seeks Extension Of Ch. 11 Plan Exclusivity Period

Drugmaker Insys Therapeutics is asking a Delaware bankruptcy judge for more time to finalize its Chapter 11 plan, saying it has a viable proposal on the table and has made progress toward an agreement with its creditors.
September 25, 2019
Gov't Claimants Want Insys Bankruptcy Converted To Ch. 7

The team leading the plaintiffs in the national opioid litigation case pending in Ohio federal court asked a Delaware bankruptcy judge to convert the Chapter 11 case of opioid maker Insys Therapeutics to a Chapter 7 liquidation because the company has sold off the bulk of its assets and is no longer operating in a meaningful way.
September 19, 2019
Insys Ch. 11 Sale Of Controversial Drug OK'd With New Limits

Insys Therapeutics Inc. received bankruptcy court approval Thursday in Delaware for a sale of its controversial pain medication Subsys after the buyer agreed to limit its marketing and distribution efforts to end-stage cancer patients.
September 09, 2019
Feds Ask To Delay Proposed Subsys Sale

The government has delayed a hearing on the proposed sale of the flagship fentanyl spray that dragged Insys Therapeutics Inc. into bankruptcy, saying the disgraced drugmaker didn't give it enough time to make sure the deal complies with various laws and regulations.
September 03, 2019
Bankrupt Insys Plans Fentanyl Spray Sale To Competitor

Bankrupt drugmaker Insys Therapeutics Inc. has reached a deal to sell the fentanyl spray painkiller that spawned its legal and financial troubles to Wyoming-based BTcP Pharma, which makes its own fentanyl spray, according to a regulatory filing Saturday.
August 29, 2019
Insys Ch. 11 Case Gets Consumer Privacy Watchdog

The Office of the U.S. Trustee filed a notice of appointment Wednesday in Delaware bankruptcy court naming a consumer privacy ombudsman to safeguard the private information of customers of pain medication maker Insys Therapeutics Inc.
August 22, 2019
Insys Ch. 11 Sales For Two Drug Lines Approved In Del.

Bankrupt pharmaceutical company Insys Therapeutics received court approval Thursday in Delaware for a pair of asset sales that will transfer certain drug lines in deals worth more than $29 million.